Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel
Chimeric antigen receptor (CAR) T-cell therapy, including axicabtagene ciloleucel (axi-cel), is efficacious for older patients. However, patients aged 65 + are at risk for more severe neurotoxicity after infusion than younger patients, and post-infusion cognitive outcomes in older patients are unknown. This study asses...